Welcome to the third edition of CVCT Asia! We are proud to have the Fondazione Internazione Menarini as the sponsor for the 2018 cardiovascular clinical trialists forum.




Carolyn Lam (Singapore)

Faiez Zannad (France)

Bertram Pitt (US)

Forum Overview

Forum by Fondazione Internazionale Menarini


Day 1 – 13 July 2018 (Friday)

1800h  Welcome reception


Day 2 – 14 July 2018 (Saturday)

0900-0915h  Opening Address

0915-1200h  Cardiovascular disease in Asia Pacific

1200-1330h  Lunch

1330-1530h  Heart failure drug trials

1530-1600h  Coffee break

1600-1800h  Biomarkers & Devices

1900h  Networking dinner 


Day 3 – 15 July 2018 (Sunday)

0900-1030h Precision medicine

1030-1100h Wrap-up & discussion

1100-1300h  Brunch

Forum Programme

Forum by Fondazione Internazionale Menarini

DAY 1 – 13 July 2018 (Friday)



DAY 2 – 14 July 2018 (Saturday)

(0900-0915h) OPENING ADDRESS

Alessandro Casini, MD

Giuseppe Caracciolo, MD, PhD



Chairpersons: Faiez Zannad (France), Bertram Pitt (US), Lijing Yan (China), Carolyn Lam (Singapore)

 This opening session serves to describe the epidemiology of cardiovascular disease in Asia Pacific, highlight the unique Asian phenotype of disease, and point out gaps in knowledge as well as unmet needs that should urgently be addressed in cardiovascular clinical trials. Large ongoing registries in Asia will be showcased, offering opportunity for collaboration. Questions to be discussed include: Are regional differences related to differences in health care systems and medical practices or due to true ethnic differences? Do Asian patients really need lower doses than Western patients? How may existing registries be upgraded so as to host registry-nested randomized trials?

(0915-0945h)  Hyperlipidemia: Genes versus diet

Asian perspective: Tavintharan Subramaniam (Singapore)

Global perspective: Kausik Ray (UK)

(0945-1015h)  Diabetes: Lean versus obese diabetic

Asian perspective: Dorairaj Prabhakaran (India)

Global perspective: Mikhail Kosiborod (US)

(1015-1045h)  Coronary artery disease: Micro- versus macro-vascular ischemia

Asian perspective: Mark Chan (Singapore)

Global perspective: Athanasios Manolis (Greece)

(1045-1115h)  Heart Failure: Preserved versus reduced ejection fraction

Asian perspective: Carolyn Lam (Singapore)

Global perspective: Adriaan Voors (Netherlands)

(1115-1200h)  Panelist Discussion

Mark Chan (Singapore)

Kausik Ray (UK)

Mikhail Kosiborod (US)

Tavintharan Subramaniam (Singapore)

Athanasios Manolis (Greece)

Adriaan Voors (Netherlands)

Dorairaj Prabhakaran (India)

Scott Wasserman (US)

Afshin Salsali (US)

Peter Fenici (US)


(1200-1330h) LUNCH



Chairpersons: Paul Armstrong (Canada), Dirk van Veldhusin (Netherlands), Myeong-Chan Cho (Korea), David Sim (Singapore)

 Recent large heart failure drug trials have changed the landscape of heart failure management and provided valuable insights into trial design. In particular, the potential geographic differences in patient populations worldwide have been highlighted. The applicability of trial findings in the diverse settings across Asia therefore deserves discussion. Heart failure trials such as RELAX-ASIA and SOCRATES demonstrate the current trend to focus on or involve Asia in combined global trial efforts, in both early and late phases of drug development. The insights gained from such efforts will be discussed.

(1330-1355h)  COMMANDER-HF

Invited Speaker: Barry Greenberg (US)

Invited Discussant for Asian perspective: Myeong-Chan Cho (Korea)

(1355-1420h)  VICTORIA
Invited Speaker: Paul Armstrong (Canada)

Invited Discussant for Asian perspective: David Sim (Singapore)

(1420-1445h)  EMPEROR

Invited Speaker: Faiez Zannad (France)

Invited Discussant for Asian perspective: Ru San Tan (Singapore)

(1445-1510h)  EFFECT-HF

Invited Speaker: Dirk van Veldhusin (Netherlands)

Invited Discussant for Asian perspective: Carolyn Lam (Singapore)

(1510-1530h)  Panelist Discussion

Barry Greenberg (US)

Ru San Tan (Singapore)

Carolyn Lam (Singapore)

Christopher Nessel (US)

Joerg Koglin (Germany)

Lothar Roessig (Germany)

Faiez Zannad (France)

Claudio Mori (Switzerland)

Afshin Salsali (US)


(1530-1600h) COFFEE BREAK



Chairpersons: Martin Huelsmann (UK), Brooke Allocco (US), Toon-Wei Lim (Singapore), Chi Keong Ching (Singapore)

 Device-based interventions are well accepted in international guidelines but remain under-used in Asia. Important geographic and/or ethnic differences may contribute to different practices across Asia. The utility of remote monitoring will be discussed, particularly within the context of Asia.

(1600-1620h) Biomarkers for risk stratification: Where we are & where we’re heading

Invited Speaker: Fred Apple (US)

Invited Discussant for Asian perspective: Arthur Mark Richards (Singapore)

 (1620-1640h) PONTIAC I & II: Biomarker-guided therapy in diabetes?

Invited Speaker: Martin Huelsmann (UK)

Invited Discussant for Asian perspective: Carolyn Lam (Singapore)

(1640-1700h) MANAGE-HF: What’s new in telemedicine?

Invited Speaker: Ken Stein (US)

Invited Discussant for Asian perspective: Raymond Wong (Singapore)

(1700-1720h) REDUCE-LAP: Device cure for HFpEF?

Invited Speaker: David Kaye (Australia)

Invited Discussant for Asian perspective: Toon-Wei Lim (Singapore)

(1720-1740h) VIP-HF: HFpEF-AF vicious twins?

Invited Speaker: Dirk van Veldhusin (Netherlands)

Invited Discussant for Asian perspective: Chi Keong Ching (Singapore)

(1740-1800h) Panelist Discussion

Fred Apple (US)

David Kaye (Australia)

Ken Stein (US)

Carolyn Lam (Singapore)

Dirk van Veldhuisen (Netherlands)

Arthur Mark Richards (Singapore)

Raymond Wong (Singapore)



DAY 3 – 15 JULY 2018 (Sunday)


Chairpersons: Fred Apple (US), Adriaan Voors (Netherlands), Khung Keong Yeo (Singapore), Patrick Tan (Singapore)

The dream of a precision medicine approach in Cardiology is becoming a reality. Wider use of electronic medical records generates big data that are being increasingly used in streamlined prospective clinical trials as well as in registry and observational studies. Results are offered as hypothesis generating or as assessments of effectiveness, occasionally challenging, and hopefully complementing, the results of randomized-controlled clinical trials. This session focuses on ongoing efforts in Asia and worldwide, and aims to discuss the far-reaching potential of this approach.


(0900-0915h) PRISM: Precision medicine in Asia

Invited Speaker: Patrick Tan (Singapore)

(0915-0930h) ATTRaCT: The Asian model

Invited Speaker: Frank Eisenhaber (Singapore)

(0930-0945h) BIOSTAT: The European model

Invited Speaker: Adriaan Voors (Netherlands)

(0945-1000h) Industry perspective on precision medicine

Invited Speaker (15 mins): Scott Wasserman (US)

(1000-1015h) Regulator’s perspective on precision medicine

Invited Speaker: Kaori Shinagawa (Japan)

(1015-1030h) Editor’s perspective on precision medicine

Invited Speaker: Stuart Spencer (UK)

(1030-1100h) WRAP-UP & DISCUSSION

Chaired by course directors Carolyn Lam (Singapore), Faiez Zannad (France), Bertram Pitt (US)



(1100-1300h) BRUNCH




To register please click here.

Symposium organized by The Meeting Lab.

Contact support@cvctasia.com for further details on registration and logistics.